{'fraction_non_alphanumeric': 0.02971931755641167, 'fraction_numerical': 0.023665382498624106, 'mean_word_length': 5.733333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Low expression of lncRNA SBF2‐AS1 regulates the miR‐302b‐3p/TGFBR2 axis, promoting metastasis in laryngeal cancer

The 5‐year survival rate of laryngeal cancer continues to decline, and the laryngeal particularity of the anatomy adversely affects the patient's quality of life. Emerging evidence suggests that long noncoding RNAs (lncRNAs) are closely correlated to key steps in the malignant progression of cancer cells. In this study, we report the role of lncRNA SBF2‐AS1/miR‐302b‐3p/TGFBR2 interactions in the metastasis of laryngeal squamous cell carcinoma (LSCC). We verified that SBF2‐AS1 was significantly downregulated in LSCC tissues and cell lines using qRT‐PCR analysis. Its low expression was correlated to lymph node metastasis and an advanced clinical stage. More importantly, LSCC patients with low expression of SBF2‐AS1 tended to have a poor prognosis. Based on this, we performed gain‐of‐function and loss‐of‐function experiments in LSCC cell lines. The results confirmed that knocking down SBF2‐AS1 can promote the metastasis of LSCC cells and enhance epithelial–mesenchymal transition phenotype, while the upregulation of SBF2‐AS1 expression resulted in the opposite. Our in vivo model verified that SBF2‐AS1 overexpression could inhibit LSCC cell metastasis. Subsequent mechanistic studies revealed that SBF2‐AS1 acted as a competing endogenous RNA that upregulated the expression of TGFBR2 by endogenous sponging for miR‐302b‐3p in LSCC cell lines. Moreover, miR‐302b‐3p overexpression reversed the inhibitory effects on LSCC metastasis induced by upregulation of SBF2‐AS1 expression, and inhibition of TGFBR2 expression reversed the effect of SBF2‐AS1 on metastasis. Our study proposes SBF2‐AS1 as a biomarker to predict the prognosis of LSCC patients and a novel potential therapeutic target.